Drug Profile
RCD 1
Alternative Names: RCD-1Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Celogos
- Class Cell therapies; Urologics
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Stress incontinence
Most Recent Events
- 28 Aug 2007 Phase II development is ongoing
- 24 Jul 2006 Phase-II clinical trials in Stress incontinence in France (Parenteral)